Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 14/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.42 |
| ▸ | CDK9 | P50750 | 7/20 | 0.42 |
| ▸ | CDK7 | P50613 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308911 | 0.82 | SCN5A (0.48) | SCN5ASMPD3FLT3PIK3CACCNT1 | |
| SCHEMBL137570 | 0.82 | FLT3 (0.40) | SMPD3FLT3PIK3CACCNT1CDK9 | |
| SCHEMBL22089810 | 0.78 | SMPD3 (0.57) | SMPD3FLT3PIK3CA | |
| SCHEMBL19102376 | 0.78 | FLT3 (0.39) | SMPD3FLT3PIK3CACCNT1CDK9 | |
| SCHEMBL139817 | 0.78 | AXL (0.47) | SMPD3FLT3PIK3CACCNT1CDK9 | |
| SCHEMBL25157822 | 0.78 | PIK3CA (0.43) | SCN5ASMPD3FLT3PIK3CACCNT1 | |
| SCHEMBL3037759 | 0.78 | FLT3 (0.39) | SMPD3FLT3PIK3CACCNT1CDK9 | |
| SCHEMBL15280676 | 0.78 | PIM1 (0.49) | SCN5ASMPD3 | |
| SCHEMBL21941666 | 0.78 | SCN5A (0.49) | SCN5ASMPD3FLT3PIK3CA | |
| SCHEMBL22330378 | 0.78 | FLT3 (0.39) | SCN5ASMPD3FLT3PIK3CACCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-109641854-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220106281-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-10913727-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2020224626-A1 | COMPOUND USED AS KINASE INHIBITOR AND APPLICATION THEREOF | 浙江同源康医药股份有限公司 | 2020-11-12 | — | — | WO | disclosed |
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119205-A1 | RADIOACTIVE FLUORINE-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD THEREFOR | 上海健康医学院 | 2020-06-18 | — | — | WO | disclosed |
| US-20190135772-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3452456-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017193063-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913727-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | SCN5A 4418/4885SMPD3 4060/4885FLT3 4726/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | SCN5A 4418/4885SMPD3 4060/4885FLT3 4726/4885 |
| US-20220106281-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | SCN5A 4418/4885SMPD3 4060/4885FLT3 4726/4885 |
| US-20190135772-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | SCN5A 4418/4885SMPD3 4060/4885FLT3 4726/4885 |
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | SCN5A 4418/4885SMPD3 4060/4885FLT3 4726/4885 |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | NR4A3, NR4A1, NR3C1 | SCN5A 122/4885SMPD3 4751/4885FLT3 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.